Korro Bio, Inc. (KRRO) — SEC Filings
Korro Bio, Inc. (KRRO) — 44 SEC filings. Latest: 10-Q (May 7, 2026). Includes 17 8-K, 7 10-Q, 7 SC 13G/A.
View Korro Bio, Inc. on SEC EDGAR
Overview
Korro Bio, Inc. (KRRO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Korro Bio, Inc. reported a net loss of $18.061 million for the three months ended September 30, 2025, a decrease from the $20.999 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $67.218 million, compared to $62.382 million in the prior year
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 40 neutral. The dominant filing sentiment for Korro Bio, Inc. is neutral.
Filing Type Overview
Korro Bio, Inc. (KRRO) has filed 7 10-Q, 17 8-K, 1 ARS, 2 DEFA14A, 1 8-K/A, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 1 S-1, 3 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of KRRO's 28 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $5,100,000 |
| Net Income | -$67,218,000 |
| EPS | N/A |
| Debt-to-Equity | 0.63 |
| Cash Position | $24,155,000 |
| Operating Margin | -139.7% |
| Total Assets | $161,550,000 |
| Total Debt | $62,518,000 |
Key Executives
- David LLucchino
- Dr. Aiyar
- Dr. Peter S. Kim
- Dr. David L. Donabedian
- Dr. Jessica Lee
- Dr. David Chang
- Dr. Marc Beer
- Dr. Michael J. Yauch
- Dr. Sarah E. Kelley
- Ali Behbahani
- Timothy Pearson
- ALI BEHBAHANI
- ANTHONY A. FLORENCE, JR.
- CARMEN CHANG
- EDWARD T. MATHERS
Industry Context
The biotechnology sector is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies often rely on strategic partnerships and collaborations for funding and market access. The current environment favors companies with strong clinical data and clear paths to commercialization, while those facing setbacks or funding challenges are under increased scrutiny.
Top Tags
corporate-governance (5) · 10-Q (4) · Korro Bio (4) · Biotechnology (3) · management-change (3) · filing (3) · financials (3) · executive-compensation (3) · 8-K (3) · KRRO (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $24.155M | Decreased from $55.643M at Dec 31, 2024, indicating significant burn. |
| Net Loss (YTD) | $67.218M | Increased from $62.382M in prior year, showing widening losses. |
| Collaboration Revenue (YTD) | $5.100M | First-time revenue, but now paused with Novo Nordisk. |
| R&D Expenses (YTD) | $54.590M | Increased from $46.674M in prior year, reflecting ongoing development costs. |
| Novo Nordisk Pause | 12 months | Duration of the collaboration pause, impacting future revenue. |
| Shares Outstanding | 9,417,295 | As of November 10, 2025, indicating potential for future dilution. |
| Net Loss | $28.3M | Increased from $25.7M in Q2 2024, indicating widening losses. |
| R&D Expenses | $20.1M | Decreased from $21.5M in Q2 2024, reflecting R&D reprioritization. |
| Cash & Equivalents | $150.5M | Down from $175.2M at year-end 2024, showing significant cash burn. |
| Contingent Value Liability | $10.2M | Represents potential future payments related to past acquisitions. |
| Reporting Period | 6 months | Covers January 1, 2025 to June 30, 2025. |
| SIC Code | 2834 | Standard Industrial Classification for Pharmaceutical Preparations |
| SEC File Number | 001-39062 | Korro Bio's SEC file number |
| Fiscal Year End | 2024 | Compensation data pertains to this year. |
| Prior Fiscal Year | 2023 | Comparative compensation data is included. |
Forward-Looking Statements
- {"claim":"Korro Bio's stock price may experience increased stability or upward pressure due to significant institutional backing from FMR LLC.","entity":"Korro Bio, Inc.","targetDate":"6-12 months","confidence":"medium"}
- {"claim":"Other institutional investors may initiate or increase their positions in Korro Bio, following FMR LLC's lead.","entity":"Korro Bio, Inc.","targetDate":"3-6 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Korro Bio, Inc. (KRRO)?
Korro Bio, Inc. has 44 recent SEC filings from Jan 2024 to May 2026, including 17 8-K, 7 10-Q, 7 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KRRO filings?
Across 44 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 40 neutral. The dominant sentiment is neutral.
Where can I find Korro Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Korro Bio, Inc. (KRRO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Korro Bio, Inc.?
Key financial highlights from Korro Bio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KRRO?
The investment thesis for KRRO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Korro Bio, Inc.?
Key executives identified across Korro Bio, Inc.'s filings include David LLucchino, Dr. Aiyar, Dr. Peter S. Kim, Dr. David L. Donabedian, Dr. Jessica Lee and 12 others.
What are the main risk factors for Korro Bio, Inc. stock?
Of KRRO's 28 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Korro Bio, Inc.?
Recent forward-looking statements from Korro Bio, Inc. include guidance on {"claim":"Korro Bio's stock price may experience increased stability or upward pressure due to significant institutional and 1 other predictions.